Vor Biopharma (NYSE:VOR) Trading Down 2.9% – Time to Sell?

Vor Biopharma Inc. (NYSE:VOR)’s stock price dropped 2.9% during trading on Tuesday . The company traded as low as $2.30 and last traded at $2.35. Approximately 6,526,475 shares traded hands during trading, a decline of 21% from the average daily volume of 8,310,444 shares. The stock had previously closed at $2.42.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. HC Wainwright upgraded Vor Biopharma from a “neutral” rating to a “buy” rating and set a $3.00 target price for the company in a research report on Monday, June 30th. Baird R W cut shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 8th. Wedbush reissued an “outperform” rating on shares of Vor Biopharma in a report on Thursday, June 26th. JMP Securities restated a “market perform” rating and issued a $6.00 target price on shares of Vor Biopharma in a research report on Friday, May 9th. Finally, Jones Trading lowered shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 8th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $5.63.

Vor Biopharma Stock Performance

The firm’s 50 day moving average price is $1.10 and its two-hundred day moving average price is $0.98. The company has a market cap of $293.66 million, a P/E ratio of -1.42 and a beta of 2.04.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in VOR. RA Capital Management L.P. grew its stake in shares of Vor Biopharma by 74.3% in the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock worth $44,007,000 after acquiring an additional 16,897,159 shares in the last quarter. Lynx1 Capital Management LP bought a new stake in shares of Vor Biopharma in the fourth quarter valued at $707,000. Jane Street Group LLC purchased a new position in shares of Vor Biopharma during the 1st quarter valued at $140,000. OMERS ADMINISTRATION Corp purchased a new stake in Vor Biopharma during the first quarter valued at about $100,000. Finally, Trustees of Columbia University in the City of New York bought a new position in Vor Biopharma in the 4th quarter worth approximately $102,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.